Trigeminal Autonomic Cephalgias (TACs) Market Outlook

Thelansis’s “Trigeminal Autonomic Cephalgias (TACs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Trigeminal Autonomic Cephalgias treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Trigeminal Autonomic Cephalgias (TACs) Overview

Trigeminal autonomic cephalgias (TACs) are a distinct group of primary headache disorders characterised by strictly unilateral, severe trigeminal distribution pain invariably accompanied by ipsilateral cranial autonomic features — lacrimation, conjunctival injection, rhinorrhoea, ptosis, and eyelid oedema — reflecting activation of the trigeminovascular system and parasympathetic outflow via the sphenopalatine ganglion. The TAC spectrum encompasses cluster headache — the most prevalent and severe form — paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and cranial autonomic features (SUNA), and hemicrania continua, each distinguished by attack duration, frequency, and critically, differential therapeutic responsiveness. Cluster headache presents with excruciating periorbital or temporal attacks lasting 15-180 minutes, occurring in episodic or chronic patterns, with high-flow oxygen and subcutaneous sumatriptan as gold-standard acute therapies and verapamil as first-line prophylaxis; galcanezumab demonstrated efficacy in episodic cluster headache prevention. Paroxysmal hemicrania and hemicrania continua exhibit absolute, diagnostically pathognomonic responses to indomethacin. SUNCT and SUNA respond preferentially to lamotrigine. Secondary TAC mimics — pituitary adenoma, cavernous sinus pathology — mandate neuroimaging exclusion. Emerging neuromodulatory approaches including sphenopalatine ganglion stimulation offer options in refractory cluster headache. Prognosis varies with TAC subtype; accurate diagnosis, subtype-specific management, and multidisciplinary headache specialist involvement are indispensable to optimising patient outcomes and quality of life.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)